Across TCGA pan-cancer cohorts, RGS11 mass-spec protein differs between tumor and matched normal tissue in 1 of 18 cancer types tested, making tumor–normal expression one of RGS11’s most consistent transcriptional readouts.
The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where RGS11 mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types RGS11 is over-expressed in tumor, although a few such as CCRCC show the opposite, repressed pattern.
CCRCC are the cancer types where RGS11 tumor–normal differential expression is most reproducible.